VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 203 filers reported holding VANDA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $794,008 | -42.2% | 183,798 | -11.8% | 0.00% | – |
| Q2 2023 | $1,373,283 | +1007.5% | 208,389 | +1734.7% | 0.00% | – |
| Q2 2022 | $124,000 | -3.1% | 11,358 | 0.0% | 0.00% | – |
| Q1 2022 | $128,000 | -31.6% | 11,358 | -4.3% | 0.00% | – |
| Q4 2021 | $187,000 | -59.4% | 11,869 | -57.8% | 0.00% | – |
| Q4 2019 | $461,000 | -69.3% | 28,122 | -73.8% | 0.00% | – |
| Q1 2017 | $1,502,000 | -43.3% | 107,313 | -35.3% | 0.00% | -100.0% |
| Q4 2016 | $2,647,000 | +199.8% | 165,959 | +112.1% | 0.00% | – |
| Q3 2015 | $883,000 | -22.4% | 78,240 | -12.7% | 0.00% | – |
| Q2 2015 | $1,138,000 | +36.5% | 89,640 | 0.0% | 0.00% | – |
| Q1 2015 | $834,000 | -41.2% | 89,640 | -9.5% | 0.00% | – |
| Q4 2014 | $1,418,000 | +25.3% | 99,010 | -9.2% | 0.00% | – |
| Q3 2014 | $1,132,000 | -44.6% | 109,100 | -13.7% | 0.00% | -100.0% |
| Q2 2014 | $2,045,000 | -0.4% | 126,400 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $2,054,000 | – | 126,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 1,532,000 | $27,423,000 | 3.23% |
| Stonepine Capital Management, LLC | 300,000 | $5,370,000 | 3.16% |
| Palo Alto Investors LP | 4,155,670 | $74,386,000 | 3.13% |
| GREAT POINT PARTNERS LLC | 497,531 | $8,906,000 | 1.73% |
| Avoro Capital Advisors LLC | 988,270 | $17,690,000 | 1.37% |
| UNIVERSITY OF NOTRE DAME DU LAC | 157,781 | $2,824,000 | 0.79% |
| Birchview Capital, LP | 68,000 | $1,217,000 | 0.63% |
| Cheyne Capital Management (UK) LLP | 74,000 | $1,323,000 | 0.48% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 352,604 | $6,311,000 | 0.43% |
| 361 CAPITAL LLC | 119,554 | $2,140,000 | 0.41% |